BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khemlina G, Ikeda S, Kurzrock R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017;16:149. [PMID: 28854942 DOI: 10.1186/s12943-017-0712-x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 167] [Article Influence: 23.4] [Reference Citation Analysis]
Number Citing Articles
1 Tang Y, Li K, Hu B, Cai Z, Li J, Tao H, Cao J. Fatty acid binding protein 5 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by degradation of Krüppel-like factor 9 mediated by miR-889-5p via cAMP-response element binding protein. Cancer Biol Ther 2022;23:424-38. [PMID: 35816613 DOI: 10.1080/15384047.2022.2094670] [Reference Citation Analysis]
2 Goodwin B, Lou J, Butchy M, Wilson T, Atabek U, Spitz F, Hong Y. Hepatocellular-Cholangiocarcinoma Collision Tumors: An Update of Current Management Practices. The American Surgeon. [DOI: 10.1177/00031348221124323] [Reference Citation Analysis]
3 Kashyap A, Tripathi G, Tripathi A, Rao R, Kashyap M, Bhat A, Kumar D, Rajhans A, Kumar P, Chandrashekar DS, Mahmood R, Husain A, Zayed H, Bharti AC, Kashyap MK. RNA splicing: a dual-edged sword for hepatocellular carcinoma. Med Oncol 2022;39:173. [PMID: 35972700 DOI: 10.1007/s12032-022-01726-8] [Reference Citation Analysis]
4 Guo C, Tang Y, Yang Z, Li G, Zhang Y. Hallmark-guided subtypes of hepatocellular carcinoma for the identification of immune-related gene classifiers in the prediction of prognosis, treatment efficacy, and drug candidates. Front Immunol 2022;13:958161. [DOI: 10.3389/fimmu.2022.958161] [Reference Citation Analysis]
5 Hu B, Gao J, Shi J, Zhang F, Shi C, Wen P, Wang Z, Guo W, Zhang S. Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma. Front Immunol 2022;13:970117. [DOI: 10.3389/fimmu.2022.970117] [Reference Citation Analysis]
6 Yu J, Sullivan BG, Senthil GN, Gonda A, Dehkordi-Vakil F, Campos B, Dayyani F, Senthil M. Prevalence of Primary Liver Cancer is Affected by Place of Birth in Hispanic People Residing in the United States: All of Us Research Program Report. Am Surg 2022;:31348221109465. [PMID: 35854430 DOI: 10.1177/00031348221109465] [Reference Citation Analysis]
7 Long S, Chen Y, Wang Y, Yao Y, Xiao S, Fu K. Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy. Cancer Med 2022. [PMID: 35841206 DOI: 10.1002/cam4.5032] [Reference Citation Analysis]
8 Weng J, Li S, Zhu Z, Liu Q, Zhang R, Yang Y, Li X. Exploring immunotherapy in colorectal cancer. J Hematol Oncol 2022;15:95. [PMID: 35842707 DOI: 10.1186/s13045-022-01294-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhang Y, Pang S, Sun B, Zhang M, Jiao X, Lai L, Qian Y, Yang N, Yang W. ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma. Front Oncol 2022;12:884066. [DOI: 10.3389/fonc.2022.884066] [Reference Citation Analysis]
10 Yu M, Yu H, Mu N, Wang Y, Ma H, Yu L. The Function of FoxK Transcription Factors in Diseases. Front Physiol 2022;13:928625. [DOI: 10.3389/fphys.2022.928625] [Reference Citation Analysis]
11 Wang S, Wu Y, Liu M, Zhao Q, Jian L. DHW-208, A Novel Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Has Anti-Hepatocellular Carcinoma Activity Through Promoting Apoptosis and Inhibiting Angiogenesis. Front Oncol 2022;12:955729. [DOI: 10.3389/fonc.2022.955729] [Reference Citation Analysis]
12 Che L, Du ZB, Wang WH, Wu JS, Han T, Chen YY, Han PY, Lei Z, Chen XX, He Y, Xu L, Lin X, Lin ZN, Lin YC. Intracellular antibody targeting HBx suppresses invasion and metastasis in hepatitis B virus-related hepatocarcinogenesis via protein phosphatase 2A-B56γ-mediated dephosphorylation of protein kinase B. Cell Prolif 2022;:e13304. [PMID: 35811356 DOI: 10.1111/cpr.13304] [Reference Citation Analysis]
13 Tang H, Yang Q, Tang Q, Li X, Ding W, Chen W. Integrated transcriptomics unravels implications of glycosylation-regulating signature in diagnosis, prognosis and therapeutic benefits of hepatocellular carcinoma. Computers in Biology and Medicine 2022. [DOI: 10.1016/j.compbiomed.2022.105886] [Reference Citation Analysis]
14 Qi W, Bai Y, Wang Y, Liu L, Zhang Y, Yu Y, Chen H. BUB1 predicts poor prognosis and immune status in liver hepatocellular carcinoma. APMIS 2022;130:371-82. [PMID: 35255180 DOI: 10.1111/apm.13219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Liu S, Huang F, Ru G, Wang Y, Zhang B, Chen X, Chu L. Mouse Models of Hepatocellular Carcinoma: Classification, Advancement, and Application. Front Oncol 2022;12:902820. [DOI: 10.3389/fonc.2022.902820] [Reference Citation Analysis]
16 Liao J, Liu Q, Chen J, Lu Z, Mo H, Jia J. A risk score model based on TGF-β pathway-related genes predicts survival, tumor microenvironment and immunotherapy for liver hepatocellular carcinoma. Proteome Sci 2022;20:11. [PMID: 35733217 DOI: 10.1186/s12953-022-00192-4] [Reference Citation Analysis]
17 Guerber L, Pangou E, Sumara I. Ubiquitin Binding Protein 2-Like (UBAP2L): is it so NICE After All? Front Cell Dev Biol 2022;10:931115. [DOI: 10.3389/fcell.2022.931115] [Reference Citation Analysis]
18 Wang C, Zhou Q, Wu ST. Scopolin obtained from Smilax china L. against hepatocellular carcinoma by inhibiting glycolysis: A network pharmacology and experimental study. J Ethnopharmacol 2022;296:115469. [PMID: 35718053 DOI: 10.1016/j.jep.2022.115469] [Reference Citation Analysis]
19 Ozeki Y, Kanogawa N, Ogasawara S, Ogawa K, Ishino T, Nakagawa M, Fujiwara K, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Kojima R, Kanzaki H, Koroki K, Kobayashi K, Nakamura M, Kiyono S, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Nakamoto S, Muroyama R, Tawada A, Chiba T, Arai M, Kato J, Ikeda JI, Takiguchi Y, Kato N. Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis. Int J Clin Oncol 2022. [PMID: 35704154 DOI: 10.1007/s10147-022-02195-9] [Reference Citation Analysis]
20 Huang S, Dong C, Li D, Xu Y, Wu J. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion. Front Cell Dev Biol 2022;10:896080. [DOI: 10.3389/fcell.2022.896080] [Reference Citation Analysis]
21 Chen X, Li W, Wu X, Zhao F, Wang D, Wu H, Gu Y, Li X, Qian X, Hu J, Li C, Xia Y, Rao J, Dai X, Shao Q, Tang J, Li X, Shu Y. Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study. Front Oncol 2022;12:909035. [DOI: 10.3389/fonc.2022.909035] [Reference Citation Analysis]
22 Xiao LS, Hu CY, Cui H, Li RN, Hong C, Li QM, Huang CY, Dong ZY, Zhu HB, Liu L. Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors. Cancer Med 2022. [PMID: 35599583 DOI: 10.1002/cam4.4818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Liu J, Zhao Z, Wei S, Li B, Zhao Z. Genomic features of Chinese small cell lung cancer. BMC Med Genomics 2022;15:117. [PMID: 35596192 DOI: 10.1186/s12920-022-01255-3] [Reference Citation Analysis]
24 Chen X, Yao D, Wang M, Wu X, Deng J, Deng H, Huang R, Lu C. Deep Sequencing of Serum Exosomal microRNA Level in Psoriasis Vulgaris Patients. Front Med 2022;9:895564. [DOI: 10.3389/fmed.2022.895564] [Reference Citation Analysis]
25 Gao Y, Zhang Z, Li Y, Chen S, Lu J, Wu L, Ma Z, Hu Y, Zhang G. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy. Front Oncol 2022;12:834564. [PMID: 35494073 DOI: 10.3389/fonc.2022.834564] [Reference Citation Analysis]
26 Salani F, Latarani M, Casadei-Gardini A, Gangadharannambiar P, Fornaro L, Vivaldi C, Pecora I, Massa V, Marisi G, Canale M, Ulivi P, Scartozzi M, Eccleston M, Masi G, Crea F. Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib. Epigenomics 2022. [PMID: 35473355 DOI: 10.2217/epi-2021-0383] [Reference Citation Analysis]
27 Teng YJ, Deng Z, Ouyang ZG, Zhou Q, Mei S, Fan XX, Wu YR, Long HP, Fang LY, Yin DL, Zhang BY, Guo YM, Zhu WH, Huang Z, Zheng P, Ning DM, Tian XF. Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway. World J Gastrointest Oncol 2022; 14(4): 872-886 [DOI: 10.4251/wjgo.v14.i4.872] [Reference Citation Analysis]
28 Sun J, Cheng N, Wang F. Comprehensive Landscape of ARID Family Members and Their Association with Prognosis and Tumor Microenvironment in Hepatocellular Carcinoma. Journal of Immunology Research 2022;2022:1-10. [DOI: 10.1155/2022/1688460] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Rah B, Rather RA, Bhat GR, Baba AB, Mushtaq I, Farooq M, Yousuf T, Dar SB, Parveen S, Hassan R, Mohammad F, Qassim I, Bhat A, Ali S, Zargar MH, Afroze D. JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies. Front Pharmacol 2022;13:821344. [DOI: 10.3389/fphar.2022.821344] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
30 Zhang Z, Liang Y, Zhong D, Dai Z, Shang J, Lai C, Zou H, Yao Y, Feng T, Huang X. Prognostic value of inflammation‐immunity‐nutrition score in patients with hepatocellular carcinoma treated with anti‐PD‐1 therapy. Clinical Laboratory Analysis. [DOI: 10.1002/jcla.24336] [Reference Citation Analysis]
31 Gao Y, Liu J, Zhao D, Diao G. A Novel Prognostic Model for Identifying the Risk of Hepatocellular Carcinoma Based on Angiogenesis Factors. Front Genet 2022;13:857215. [DOI: 10.3389/fgene.2022.857215] [Reference Citation Analysis]
32 Liao H, Jiang H, Chen Y, Duan T, Yang T, Han M, Xue Z, Shi F, Yuan K, Bashir MR, Shen D, Song B, Zeng Y. Predicting Genomic Alterations of Phosphatidylinositol-3 Kinase Signaling in Hepatocellular Carcinoma: A Radiogenomics Study Based on Next-Generation Sequencing and Contrast-Enhanced CT. Ann Surg Oncol 2022. [PMID: 35286532 DOI: 10.1245/s10434-022-11505-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Zhang S, Xu L, Feng J, Tan D, Zhu Y, Hou J, Li W, Lv K, Wang W, Jiang L, Jiao M, Guo H. ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma. Front Genet 2022;13:842351. [DOI: 10.3389/fgene.2022.842351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Yang S, Cai C, Wang H, Ma X, Shao A, Sheng J, Yu C. Drug delivery strategy in hepatocellular carcinoma therapy. Cell Commun Signal 2022;20. [DOI: 10.1186/s12964-021-00796-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Lin Z, Xu Q, Song X, Zeng Y, Zeng L, Zhao L, Xu J, Miao D, Chen Z, Yu F. Comprehensive Analysis Identified Mutation-Gene Signature Impacts the Prognosis Through Immune Function in Hepatocellular Carcinoma. Front Oncol 2022;12:748557. [DOI: 10.3389/fonc.2022.748557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Dimin N, Zhe D, Yongrong W, Si M, Yongjie T, Qing Z, Xuefei T. Niuhuang (Bovis Calculus)-Shexiang (Moschus) combination induces apoptosis and inhibits proliferation in hepatocellular carcinoma via PI3K/AKT/mTOR pathway. Digital Chinese Medicine 2022;5:83-92. [DOI: 10.1016/j.dcmed.2022.03.009] [Reference Citation Analysis]
37 Liu D, Wu M, Zhang T, Wang C. Ferroptosis Regulator Modification Patterns and Tumor Microenvironment Immune Infiltration Characterization in Hepatocellular Carcinoma. Front Mol Biosci 2022;9:807502. [DOI: 10.3389/fmolb.2022.807502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Yao F, Zhan Y, Li C, Lu Y, Chen J, Deng J, Wu Z, Li Q, Song Y, Chen B, Chen J, Tian K, Pu Z, Ni Y, Mou L. Single-Cell RNA Sequencing Reveals the Role of Phosphorylation-Related Genes in Hepatocellular Carcinoma Stem Cells. Front Cell Dev Biol 2021;9:734287. [PMID: 35059393 DOI: 10.3389/fcell.2021.734287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Yan Z, Zhou Y, Yang Y, Zeng C, Li P, Tian H, Tang X, Zhang G. Zinc finger protein 384 enhances colorectal cancer metastasis by upregulating MMP2. Oncol Rep 2022;47:49. [PMID: 35029289 DOI: 10.3892/or.2022.8260] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Cui H, Guo D, Zhang X, Zhu Y, Wang Z, Jin Y, Guo W, Zhang S. ENO3 Inhibits Growth and Metastasis of Hepatocellular Carcinoma via Wnt/β-Catenin Signaling Pathway. Front Cell Dev Biol 2021;9:797102. [PMID: 35004693 DOI: 10.3389/fcell.2021.797102] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
41 Huang S, Zhang J, Lai X, Zhuang L, Wu J. Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients. Front Mol Biosci 2021;8:781307. [PMID: 35004851 DOI: 10.3389/fmolb.2021.781307] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
42 Wang Z, Zuo J, Zhang L, Zhang Z, Wei Y. Plantamajoside promotes metformin-induced apoptosis, autophagy and proliferation arrest of liver cancer cells via suppressing Akt/GSK3β signaling. Hum Exp Toxicol 2022;41:9603271221078868. [PMID: 35350904 DOI: 10.1177/09603271221078868] [Reference Citation Analysis]
43 Li W, Wang Y, Zhou X, Pan X, Lü J, Sun H, Xie Z, Chen S, Gao X. The anti-tumor efficacy of 20(S)-protopanaxadiol, an active metabolite of ginseng, according to fasting on hepatocellular carcinoma. Journal of Ginseng Research 2022;46:167-74. [DOI: 10.1016/j.jgr.2021.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Wang Z, Yang X, Gui S, Yang F, Cao Z, Cheng R, Xia X, Li C. The Roles and Mechanisms of lncRNAs in Liver Fibrosis. Front Pharmacol 2021;12:779606. [PMID: 34899344 DOI: 10.3389/fphar.2021.779606] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Zhou YQ, Sun Y, Luo HL, Gao ZF, Zhang HQ, Meng QG, Bai XY, Hou GG, Hou Y. Discovery of anti-hepatoma agents from 1,4,5,6,7,8-hexahydropyrido[4,3-d]pyrimidine by inhibiting PI3K/AKT/NF-κB pathway activation. Eur J Med Chem 2021;225:113796. [PMID: 34450496 DOI: 10.1016/j.ejmech.2021.113796] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Pan C, Nie W, Wang J, Du J, Pan Z, Gao J, Lu Y, Che J, Zhu H, Dai H, Chen B, He Q, Dong X. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors. Eur J Med Chem 2021;225:113794. [PMID: 34488024 DOI: 10.1016/j.ejmech.2021.113794] [Reference Citation Analysis]
47 Kazmi I, Al-Abbasi FA, Afzal M, Altayb HN, Nadeem MS, Gupta G. Formulation and Evaluation of Kaempferol Loaded Nanoparticles against Experimentally Induced Hepatocellular Carcinoma: In Vitro and In Vivo Studies. Pharmaceutics 2021;13:2086. [PMID: 34959368 DOI: 10.3390/pharmaceutics13122086] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
48 Rios RS, Zheng KI, Zheng MH. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2911-21. [PMID: 34855640 DOI: 10.1097/CM9.0000000000001888] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
49 Bao L, Li P, Zhao H, Chen L, Wang Y, Liang S, Liu J. Pseudogene PLGLA exerts anti-tumor effects on hepatocellular carcinoma through modulating miR-324-3p/GLYATL1 axis. Dig Liver Dis 2021:S1590-8658(21)00808-2. [PMID: 34782279 DOI: 10.1016/j.dld.2021.10.003] [Reference Citation Analysis]
50 Karan D. CCL23 in Balancing the Act of Endoplasmic Reticulum Stress and Antitumor Immunity in Hepatocellular Carcinoma. Front Oncol 2021;11:727583. [PMID: 34671553 DOI: 10.3389/fonc.2021.727583] [Reference Citation Analysis]
51 Tian Y, Komolafe TE, Zheng J, Zhou G, Chen T, Zhou B, Yang X. Assessing PD-L1 Expression Level via Preoperative MRI in HCC Based on Integrating Deep Learning and Radiomics Features. Diagnostics (Basel) 2021;11:1875. [PMID: 34679573 DOI: 10.3390/diagnostics11101875] [Reference Citation Analysis]
52 Sun R, Fang L, Lv X, Fang J, Wang Y, Chen D, Wang L, Chen J, Qi Y, Tang Z, Zhang J, Tian Y. In vitro and in vivo evaluation of self-assembled chitosan nanoparticles selectively overcoming hepatocellular carcinoma via asialoglycoprotein receptor. Drug Deliv 2021;28:2071-84. [PMID: 34595970 DOI: 10.1080/10717544.2021.1983077] [Reference Citation Analysis]
53 Khamis ZI, Pang X, Cui Z, Sang QA, Zhang J. Cytochrome P450-2D6: A novel biomarker in liver cancer health disparity. PLoS One 2021;16:e0257072. [PMID: 34597305 DOI: 10.1371/journal.pone.0257072] [Reference Citation Analysis]
54 Xue C, Gu X, Li L. Immune classifier-based signatures provide good prognostic stratification and predict the clinical benefits of immune-based therapies for hepatocellular carcinoma. Cancer Cell Int 2021;21:471. [PMID: 34488768 DOI: 10.1186/s12935-021-02183-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
55 Lee HH, Kim D, Jung J, Kang H, Cho H. NLRP3 Deficiency in Hepatocellular Carcinoma Enhances Surveillance of NK-92 through a Modulation of MICA/B. Int J Mol Sci 2021;22:9285. [PMID: 34502191 DOI: 10.3390/ijms22179285] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
56 Chae H, Sung PS, Choi H, Kwon A, Kang D, Kim Y, Kim M, Yoon SK. Targeted Next-Generation Sequencing of Plasma Cell-Free DNA in Korean Patients with Hepatocellular Carcinoma. Ann Lab Med 2021;41:198-206. [PMID: 33063681 DOI: 10.3343/alm.2021.41.2.198] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Luo J, Lu C, Feng M, Dai L, Wang M, Qiu Y, Zheng H, Liu Y, Li L, Tang B, Xu C, Wang Y, Yang X. Cooperation between liver-specific mutations of pten and tp53 genetically induces hepatocarcinogenesis in zebrafish. J Exp Clin Cancer Res 2021;40:262. [PMID: 34416907 DOI: 10.1186/s13046-021-02061-y] [Reference Citation Analysis]
58 Borhani AA, Catania R, Velichko YS, Hectors S, Taouli B, Lewis S. Radiomics of hepatocellular carcinoma: promising roles in patient selection, prediction, and assessment of treatment response. Abdom Radiol (NY) 2021;46:3674-85. [PMID: 33891149 DOI: 10.1007/s00261-021-03085-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
59 Liu Z, Wang A, Pu Y, Li Z, Xue R, Zhang C, Xiang X, E JY, Bu Z, Bai F, Ji J. Genomic and transcriptomic profiling of hepatoid adenocarcinoma of the stomach. Oncogene 2021. [PMID: 34326469 DOI: 10.1038/s41388-021-01976-2] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
60 Chen H, Bao L, Hu J, Wu D, Tong X. ORC6, Negatively Regulated by miR-1-3p, Promotes Proliferation, Migration, and Invasion of Hepatocellular Carcinoma Cells. Front Cell Dev Biol 2021;9:652292. [PMID: 34395415 DOI: 10.3389/fcell.2021.652292] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
61 Sun L, Jiang Y, Yan X, Dai X, Huang C, Chen L, Li T, Zhang Y, Xiao H, Yang M, Xiang L, Zhang Y, Chen S, Li S, Chen A, He F, Lian J. Dichloroacetate enhances the anti-tumor effect of sorafenib via modulating the ROS-JNK-Mcl-1 pathway in liver cancer cells. Exp Cell Res 2021;406:112755. [PMID: 34332981 DOI: 10.1016/j.yexcr.2021.112755] [Reference Citation Analysis]
62 Wang Y, Pei L, Yue Z, Jia M, Wang H, Cao LL. The Potential of Serum Exosomal hsa_circ_0028861 as the Novel Diagnostic Biomarker of HBV-Derived Hepatocellular Cancer. Front Genet 2021;12:703205. [PMID: 34367259 DOI: 10.3389/fgene.2021.703205] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
63 Mir IH, Guha S, Behera J, Thirunavukkarasu C. Targeting molecular signal transduction pathways in hepatocellular carcinoma and its implications for cancer therapy. Cell Biol Int 2021. [PMID: 34270844 DOI: 10.1002/cbin.11670] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
64 Zhou D, Luan J, Huang C, Li J. Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe? Gut Liver 2021;15:500-16. [PMID: 33087588 DOI: 10.5009/gnl20223] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
65 Woei-A-Jin FJSH, Weijl NI, Burgmans MC, Fariña Sarasqueta A, van Wezel JT, Wasser MNJM, Coenraad MJ, Burggraaf J, Osanto S. Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study. Oncologist 2021. [PMID: 34251745 DOI: 10.1002/onco.13901] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
66 Jiao J, Sanchez JI, Thompson EJ, Mao X, McCormick JB, Fisher-Hoch SP, Futreal PA, Zhang J, Beretta L. Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics. Int J Mol Sci 2021;22:7411. [PMID: 34299031 DOI: 10.3390/ijms22147411] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Xia P, Zhang H, Xu K, Jiang X, Gao M, Wang G, Liu Y, Yao Y, Chen X, Ma W, Zhang Z, Yuan Y. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma. Cell Death Dis 2021;12:691. [PMID: 34244479 DOI: 10.1038/s41419-021-03973-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 26] [Article Influence: 1.0] [Reference Citation Analysis]
68 Zhao X, Wang J, Deng Y, Liao L, Zhou M, Peng C, Li Y. Quercetin as a protective agent for liver diseases: A comprehensive descriptive review of the molecular mechanism. Phytother Res 2021. [PMID: 34159683 DOI: 10.1002/ptr.7104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
69 Wang P, Li Y, Li L, Zhong R, Shen N. MBOAT7-TMC4 rs641738 Is Not Associated With the Risk of Hepatocellular Carcinoma or Persistent Hepatitis B Infection. Front Oncol 2021;11:639438. [PMID: 34113561 DOI: 10.3389/fonc.2021.639438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
70 Shao M, Shi R, Gao ZX, Gao SS, Li JF, Li H, Cui SZ, Hu WM, Chen TY, Wu GR, Zhang J, Xu J, Sy MS, Li C. Crizotinib and Doxorubicin Cooperatively Reduces Drug Resistance by Mitigating MDR1 to Increase Hepatocellular Carcinoma Cells Death. Front Oncol 2021;11:650052. [PMID: 34094940 DOI: 10.3389/fonc.2021.650052] [Reference Citation Analysis]
71 He Y, Tao W, Shang C, Qi C, Ji D, Lu W, Chen G. Xeroderma Pigmentosum group D suppresses proliferation and promotes apoptosis of HepG2 cells by downregulating ERG expression via the PPARγ pathway. Int J Exp Pathol 2021;102:157-62. [PMID: 33993564 DOI: 10.1111/iep.12396] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Yan Q, Zheng W, Wang B, Ye B, Luo H, Yang X, Zhang P, Wang X. A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma. BioData Min 2021;14:29. [PMID: 33962640 DOI: 10.1186/s13040-021-00261-y] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
73 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Li Y, Zheng Y, Wu L, Li J, Ji J, Yu Q, Dai W, Feng J, Wu J, Guo C. Current status of ctDNA in precision oncology for hepatocellular carcinoma. J Exp Clin Cancer Res 2021;40:140. [PMID: 33902698 DOI: 10.1186/s13046-021-01940-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
75 Wong M, Waters KM, Guindi M, Larson BK. New Names for Old Tumors. Am J Clin Pathol 2021;155:698-710. [PMID: 33258899 DOI: 10.1093/ajcp/aqaa184] [Reference Citation Analysis]
76 Sun X, Zhu H, Cao R, Zhang J, Wang X. BACH1 is transcriptionally inhibited by TET1 in hepatocellular carcinoma in a microRNA-34a-dependent manner to regulate autophagy and inflammation. Pharmacol Res 2021;169:105611. [PMID: 33878446 DOI: 10.1016/j.phrs.2021.105611] [Reference Citation Analysis]
77 Ou Y, Deng Y, Wang H, Zhang Q, Luo H, Hu P. Targeting Antisense lncRNA PRKAG2-AS1, as a Therapeutic Target, Suppresses Malignant Behaviors of Hepatocellular Carcinoma Cells. Front Med (Lausanne) 2021;8:649279. [PMID: 33928106 DOI: 10.3389/fmed.2021.649279] [Reference Citation Analysis]
78 Gao W, Li L, Han X, Liu S, Li C, Yu G, Zhang L, Zhang D, Liu C, Meng E, Hong S, Wang D, Guo P, Shi G. Comprehensive analysis of immune-related prognostic genes in the tumour microenvironment of hepatocellular carcinoma. BMC Cancer 2021;21:331. [PMID: 33789609 DOI: 10.1186/s12885-021-08052-8] [Reference Citation Analysis]
79 Zhang Z, Chen P, Xie H, Cao P. Overexpression of GINS4 Is Associated With Tumor Progression and Poor Survival in Hepatocellular Carcinoma. Front Oncol 2021;11:654185. [PMID: 33842367 DOI: 10.3389/fonc.2021.654185] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
80 Lin W, Zhang T, Ding G, Hao L, Zhang B, Yu J, Pang Y, Geng F, Zhan L, Zhou M, Yan Q, Wang Y, Zheng C, Li H. Circular RNA circ‑CCT3 promotes hepatocellular carcinoma progression by regulating the miR‑1287‑5p/TEAD1/PTCH1/LOX axis. Mol Med Rep 2021;23:375. [PMID: 33760147 DOI: 10.3892/mmr.2021.12014] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
81 Xie C, Wu H, Pan T, Zheng X, Yang X, Zhang G, Lian Y, Lin J, Peng L. A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma. Aging (Albany NY) 2021;13:8563-87. [PMID: 33714200 DOI: 10.18632/aging.202670] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
82 Qiu YA, Xiong J, Fu Q, Dong Y, Liu M, Peng M, Jin W, Zhou L, Xu X, Huang X, Fu A, Xu G, Tu G, Yu T. GPER-Induced ERK Signaling Decreases Cell Viability of Hepatocellular Carcinoma. Front Oncol 2021;11:638171. [PMID: 33767999 DOI: 10.3389/fonc.2021.638171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Yu M, Xu W, Jie Y, Pang J, Huang S, Cao J, Gong J, Li X, Chong Y. Identification and validation of three core genes in p53 signaling pathway in hepatitis B virus-related hepatocellular carcinoma. World J Surg Oncol 2021;19:66. [PMID: 33685467 DOI: 10.1186/s12957-021-02174-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
84 Deng T, Ye Q, Jin C, Wu M, Chen K, Yang J, Chen Z, Yu X, Chen G, Wang Y. Identification and validation of a glycolysis-associated multiomics prognostic model for hepatocellular carcinoma. Aging (Albany NY) 2021;13:7481-98. [PMID: 33686959 DOI: 10.18632/aging.202613] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Xue C, Li G, Lu J, Luo J, Jia J. Novel insights for lncRNA MAGI2-AS3 in solid tumors. Biomed Pharmacother 2021;137:111429. [PMID: 33761624 DOI: 10.1016/j.biopha.2021.111429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
86 Zhu M, Wu M, Bian S, Song Q, Xiao M, Huang H, You L, Zhang J, Zhang J, Cheng C, Ni W, Zheng W. DNA primase subunit 1 deteriorated progression of hepatocellular carcinoma by activating AKT/mTOR signaling and UBE2C-mediated P53 ubiquitination. Cell Biosci 2021;11:42. [PMID: 33622397 DOI: 10.1186/s13578-021-00555-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
87 Zhang RY, Liu ZK, Wei D, Yong YL, Lin P, Li H, Liu M, Zheng NS, Liu K, Hu CX, Yang XZ, Chen ZN, Bian H. UBE2S interacting with TRIM28 in the nucleus accelerates cell cycle by ubiquitination of p27 to promote hepatocellular carcinoma development. Signal Transduct Target Ther 2021;6:64. [PMID: 33589597 DOI: 10.1038/s41392-020-00432-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
88 Peng Y, Liu C, Li M, Li W, Zhang M, Jiang X, Chang Y, Liu L, Wang F, Zhao Q. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma. Cancer Cell Int 2021;21:98. [PMID: 33568167 DOI: 10.1186/s12935-021-01792-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
89 Tang X, Ren H, Guo M, Qian J, Yang Y, Gu C. Review on circular RNAs and new insights into their roles in cancer. Comput Struct Biotechnol J 2021;19:910-28. [PMID: 33598105 DOI: 10.1016/j.csbj.2021.01.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
90 Kwee SA, Tiirikainen M. Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers. Hepatoma Res 2021;7:8. [PMID: 33553649 DOI: 10.20517/2394-5079.2020.124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
91 Lewis S, Hectors S, Taouli B. Radiomics of hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:111-23. [PMID: 31925492 DOI: 10.1007/s00261-019-02378-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 21.0] [Reference Citation Analysis]
92 Chen L, Yi C, Li W, Tseng Y, Zhang J, Liu J. Inhibition of SPATS2 Suppresses Proliferation and Invasion of Hepatocellular Carcinoma Cells through TRIM44-STAT3 Signaling Pathway. J Cancer 2021;12:89-98. [PMID: 33391405 DOI: 10.7150/jca.47526] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
93 Perera S, Kelly D, O'Kane GM. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease. Curr Oncol 2020;27:S165-72. [PMID: 33343210 DOI: 10.3747/co.27.7159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
94 Liu X, Shen Z. LncRNA TMPO-AS1 Aggravates the Development of Hepatocellular Carcinoma via miR-429/GOT1 Axis. The American Journal of the Medical Sciences 2020;360:711-20. [DOI: 10.1016/j.amjms.2020.08.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
95 Feng YX, Li W, Wen XD, Zhang N, Liu WH, Yang ZY. Sinusoidal Endothelial Cell Progenitor Cells Promote Tumour Progression in Patients with Hepatocellular Carcinoma. Stem Cells Int 2020;2020:8819523. [PMID: 33312206 DOI: 10.1155/2020/8819523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Liu P, Tang Q, Chen M, Chen W, Lu Y, Liu Z, He Z. Hepatocellular Senescence: Immunosurveillance and Future Senescence-Induced Therapy in Hepatocellular Carcinoma. Front Oncol 2020;10:589908. [PMID: 33330071 DOI: 10.3389/fonc.2020.589908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
97 Zhao Z, Song J, Tang B, Fang S, Zhang D, Zheng L, Wu F, Gao Y, Chen C, Hu X, Weng Q, Yang Y, Tu J, Ji J. CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway. J Exp Clin Cancer Res 2020;39:259. [PMID: 33234142 DOI: 10.1186/s13046-020-01769-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
98 Yu H, Bai Y, Xu C, He X, Liu Q, Ma D, A Y. The tissue expression levels of SUMO1P 3 may be a reliable prognostic biomarker to predict the clinical outcomes in patients with HCC. Medicine (Baltimore) 2020;99:e21291. [PMID: 33181633 DOI: 10.1097/MD.0000000000021291] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Huang Y, Liu C, Zeng WC, Xu GY, Wu JM, Li ZW, Huang XY, Lin RJ, Shi X. Isoliquiritigenin inhibits the proliferation, migration and metastasis of Hep3B cells via suppressing cyclin D1 and PI3K/AKT pathway. Biosci Rep 2020;40:BSR20192727. [PMID: 31840737 DOI: 10.1042/BSR20192727] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
100 Yao L, Xuan Y, Zhang H, Yang B, Ma X, Wang T, Meng T, Sun W, Wei H, Ma X, Moses R, Xiao J, Zhang P, Ge C, Li J, Li L, Li X, Li J, Zhang B. Reciprocal REGγ-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma. Oncogene 2021;40:677-92. [PMID: 33230243 DOI: 10.1038/s41388-020-01558-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
101 Zeng XC, Zhang L, Liao WJ, Ao L, Lin ZM, Kang W, Chen WN, Lin X. Screening and Identification of Potential Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma by Bioinformatics Analysis. Front Genet 2020;11:555537. [PMID: 33193629 DOI: 10.3389/fgene.2020.555537] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
102 Chen S, Huang Z, Jia W, Tao H, Zhang S, Ma J, Liu Z, Wang J, Wang L, Cui P, Zhang Z, Huang D, Wu Z, Zheng X, Hu Y. Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors. J Hepatocell Carcinoma 2020;7:289-99. [PMID: 33173757 DOI: 10.2147/JHC.S277453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
103 Pourhanifeh MH, Vosough M, Mahjoubin-tehran M, Hashemipour M, Nejati M, Abbasi-kolli M, Sahebkar A, Mirzaei H. Autophagy-related microRNAs: Possible regulatory roles and therapeutic potential in and gastrointestinal cancers. Pharmacological Research 2020;161:105133. [DOI: 10.1016/j.phrs.2020.105133] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
104 Yan W, Cheng L, Zhang D. Ultrasound-Targeted Microbubble Destruction Mediated si-CyclinD1 Inhibits the Development of Hepatocellular Carcinoma via Suppression of PI3K/AKT Signaling Pathway. Cancer Manag Res 2020;12:10829-39. [PMID: 33149688 DOI: 10.2147/CMAR.S263590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
105 Chen W, Tang D, Tang D, Dai Y. Epigenetic silencing of ZIC4 contributes to cancer progression in hepatocellular carcinoma. Cell Death Dis 2020;11:906. [PMID: 33097694 DOI: 10.1038/s41419-020-03109-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Xiao X, Mo H, Tu K. CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression. Int Immunopharmacol 2020;89:107043. [PMID: 33039961 DOI: 10.1016/j.intimp.2020.107043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
107 Ma XL, Qu XD, Yang WJ, Wang BL, Shen MN, Zhou Y, Zhang CY, Sun YF, Chen JW, Hu B, Gong ZJ, Zhang X, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization. Clin Chim Acta 2020;511:67-74. [PMID: 32979338 DOI: 10.1016/j.cca.2020.09.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
108 Chen W, Zhang X, Bi K, Zhou H, Xu J, Dai Y, Diao H. Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance. Front Oncol 2020;10:554165. [PMID: 33072579 DOI: 10.3389/fonc.2020.554165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
109 Huo J, Wu L, Zang Y. Development and Validation of a Novel Immune-Gene Pairs Prognostic Model Associated with CTNNB1 Alteration in Hepatocellular Carcinoma. Med Sci Monit 2020;26:e925494. [PMID: 32945289 DOI: 10.12659/MSM.925494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
110 Xu D, Wang Y, Zhou K, Wu J, Zhang Z, Zhang J, Yu Z, Liu L, Liu X, Li B, Zheng J. Development and Validation of a Novel 8 Immune Gene Prognostic Signature Based on the Immune Expression Profile for Hepatocellular Carcinoma. Onco Targets Ther 2020;13:8125-40. [PMID: 32884295 DOI: 10.2147/OTT.S263047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
111 Kong J, Zhang Q, Liang X, Sun W. FOXK2 downregulation suppresses EMT in hepatocellular carcinoma. Open Med (Wars) 2020;15:702-8. [PMID: 33313412 DOI: 10.1515/med-2020-0129] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
112 Cai M, Shao W, Yu H, Hong Y, Shi L. Paeonol Inhibits Cell Proliferation, Migration and Invasion and Induces Apoptosis in Hepatocellular Carcinoma by Regulating miR-21-5p/KLF6 Axis. Cancer Manag Res 2020;12:5931-43. [PMID: 32765094 DOI: 10.2147/CMAR.S254485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
113 Ji B, Cai H, Yang Y, Peng F, Song M, Sun K, Yan F, Liu Y. Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma. Acta Biomater 2020;111:363-72. [PMID: 32434082 DOI: 10.1016/j.actbio.2020.04.046] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 12.0] [Reference Citation Analysis]
114 Su Y, Xu C, Liu Y, Hu Y, Wu H. Circular RNA hsa_circ_0001649 inhibits hepatocellular carcinoma progression via multiple miRNAs sponge. Aging (Albany NY) 2019;11:3362-75. [PMID: 31137016 DOI: 10.18632/aging.101988] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 17.0] [Reference Citation Analysis]
115 Hu B, Yang XB, Sang XT. Construction of a new immune-related signature based on three lncRNAs as the factor for prognosis prediction of hepatocellular carcinoma. Clin Transl Med 2020;10:e101. [PMID: 32526096 DOI: 10.1002/ctm2.101] [Reference Citation Analysis]
116 Fei Q, Song F, Jiang X, Hong H, Xu X, Jin Z, Zhu X, Dai B, Yang J, Sui C, Xu M. LncRNA ST8SIA6-AS1 promotes hepatocellular carcinoma cell proliferation and resistance to apoptosis by targeting miR-4656/HDAC11 axis. Cancer Cell Int 2020;20:232. [PMID: 32536820 DOI: 10.1186/s12935-020-01325-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
117 Shao Z, Pan Q, Zhang Y. Hepatocellular carcinoma cell-derived extracellular vesicles encapsulated microRNA-584-5p facilitates angiogenesis through PCK1-mediated nuclear factor E2-related factor 2 signaling pathway. Int J Biochem Cell Biol 2020;125:105789. [PMID: 32522621 DOI: 10.1016/j.biocel.2020.105789] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
118 Shen N, Wang P, Li Y, Zhu Y, Gong Y, Zhong R, Lu Y, Cheng L. Nonreceptor protein tyrosine phosphatases (NRPTPs) gene family associates with the risk of hepatocellular carcinoma in a Chinese hepatitis B virus-related subjects. Mol Carcinog 2020;59:980-8. [PMID: 32484301 DOI: 10.1002/mc.23228] [Reference Citation Analysis]
119 Cui Y, Liang S, Zhang S, Zhang C, Zhao Y, Wu D, Wang J, Song R, Wang J, Yin D, Liu Y, Pan S, Liu X, Wang Y, Han J, Meng F, Zhang B, Guo H, Lu Z, Liu L. ABCA8 is regulated by miR-374b-5p and inhibits proliferation and metastasis of hepatocellular carcinoma through the ERK/ZEB1 pathway. J Exp Clin Cancer Res 2020;39:90. [PMID: 32430024 DOI: 10.1186/s13046-020-01591-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
120 Dharmapuri S, Özbek U, Lin JY, Sung M, Schwartz M, Branch AD, Ang C. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy. Cancer Med 2020;9:4962-70. [PMID: 32419290 DOI: 10.1002/cam4.3135] [Cited by in Crossref: 12] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
121 Zhang C, Shen L, Yuan W, Liu Y, Guo R, Luo Y, Zhan Z, Xie Z, Wu G, Wu W, Feng Y. Loss of SRSF2 triggers hepatic progenitor cell activation and tumor development in mice. Commun Biol 2020;3:210. [PMID: 32372053 DOI: 10.1038/s42003-020-0893-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
122 da Silva EFG, Lima KG, Krause GC, Haute GV, Pedrazza L, Catarina AV, Gassen RB, de Souza Basso B, Dias HB, Luft C, Garcia MCR, Costa BP, Antunes GL, Basso LA, Donadio MVF, Machado P, de Oliveira JR. CPBMF65, a synthetic human uridine phosphorylase-1 inhibitor, reduces HepG2 cell proliferation through cell cycle arrest and senescence. Invest New Drugs 2020;38:1653-63. [DOI: 10.1007/s10637-020-00941-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Wang P, Peng J, Gong Y, Shen N. CDC25B is associated with the risk of hepatocellular carcinoma, but not related to persistent infection of hepatitis B virus in a Chinese population. Mol Biol Rep 2020;47:3361-8. [PMID: 32248384 DOI: 10.1007/s11033-020-05408-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
124 Ge PL, Li SF, Wang WW, Li CB, Fu YB, Feng ZK, Li L, Zhang G, Gao ZQ, Dang XW, Wu Y. Prognostic values of immune scores and immune microenvironment-related genes for hepatocellular carcinoma. Aging (Albany NY). 2020;12:5479-5499. [PMID: 32213661 DOI: 10.18632/aging.102971] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
125 Hu B, Yang XB, Sang XT. Development of an immune-related prognostic index associated with hepatocellular carcinoma. Aging (Albany NY) 2020;12:5010-30. [PMID: 32191631 DOI: 10.18632/aging.102926] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
126 Zhang BH, Yang J, Jiang L, Lyu T, Kong LX, Tan YF, Li B, Zhu YF, Xi AY, Xu X, Yan LN, Yang JY. Development and validation of a 14-gene signature for prognosis prediction in hepatocellular carcinoma. Genomics 2020;112:2763-71. [PMID: 32198063 DOI: 10.1016/j.ygeno.2020.03.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
127 Wang P, Wu C, Li Y, Gong Y, Shen N. PNPLA3 rs738409 is not associated with the risk of hepatocellular carcinoma and persistent infection of hepatitis B virus (HBV) in HBV-related subjects: A case-control study and meta-analysis on Asians. Gene 2020;742:144585. [PMID: 32173542 DOI: 10.1016/j.gene.2020.144585] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Ni Q, Chen Z, Zheng Q, Xie D, Li JJ, Cheng S, Ma X. Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway. Cancer Sci 2020;111:1500-13. [PMID: 31997489 DOI: 10.1111/cas.14331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
129 Peisen F, Maurer M, Grosse U, Nikolaou K, Syha R, Ketelsen D, Artzner C, Bitzer M, Horger M, Grözinger G. Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE). Eur Radiol 2020;30:3782-92. [PMID: 32125515 DOI: 10.1007/s00330-020-06734-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
130 Zhao JT, Chi BJ, Sun Y, Chi NN, Zhang XM, Sun JB, Chen Y, Xia Y. LINC00174 is an oncogenic lncRNA of hepatocellular carcinoma and regulates miR-320/S100A10 axis. Cell Biochem Funct 2020;38:859-69. [PMID: 32128852 DOI: 10.1002/cbf.3498] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
131 Li ZB, Chu HT, Jia M, Li L. Long noncoding RNA LINC01139 promotes the progression of hepatocellular carcinoma by upregulating MYBL2 via competitively binding to miR-30 family. Biochem Biophys Res Commun 2020;525:581-8. [PMID: 32115147 DOI: 10.1016/j.bbrc.2020.02.116] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
132 Wang L, Zhan Y, Wu Z, Lin M, Jin X, Jiang L, Qiu Y. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells. Biomed Pharmacother 2020;125:110033. [PMID: 32187962 DOI: 10.1016/j.biopha.2020.110033] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
133 Hectors SJ, Lewis S, Besa C, King MJ, Said D, Putra J, Ward S, Higashi T, Thung S, Yao S, Laface I, Schwartz M, Gnjatic S, Merad M, Hoshida Y, Taouli B. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. Eur Radiol. 2020;30:3759-3769. [PMID: 32086577 DOI: 10.1007/s00330-020-06675-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
134 Zhang X, Yan Z, Wang L, Zhang S, Gao M. STAT1-induced upregulation of lncRNA RHPN1-AS1 predicts a poor prognosis of hepatocellular carcinoma and contributes to tumor progression via the miR-485/CDCA5 axis. J Cell Biochem 2020. [PMID: 32065447 DOI: 10.1002/jcb.29689] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
135 Folschette M, Legagneux V, Poret A, Chebouba L, Guziolowski C, Théret N. A pipeline to create predictive functional networks: application to the tumor progression of hepatocellular carcinoma. BMC Bioinformatics 2020;21:18. [PMID: 31937236 DOI: 10.1186/s12859-019-3316-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Liao Y. Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma. Genes Dis 2020;7:291-8. [PMID: 32884983 DOI: 10.1016/j.gendis.2019.12.014] [Reference Citation Analysis]
137 Pan X, Lin P, Feng F, Li J, Li Y, Dai W, Hu B, Yang X, Fan J, Li H, Li Y. Comparison of immune profiles between hepatocellular carcinoma subtypes. Biophys Rep 2020;6:19-32. [DOI: 10.1007/s41048-019-00102-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Zhou Z, Li Y, Hao H, Wang Y, Zhou Z, Wang Z, Chu X. Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis. Cell Transplant 2019;28:76S-86S. [PMID: 31822116 DOI: 10.1177/0963689719893950] [Cited by in Crossref: 18] [Cited by in F6Publishing: 44] [Article Influence: 6.0] [Reference Citation Analysis]
139 Cai QY, Jiang JH, Jin RM, Jin GZ, Jia NY. The clinical significance of lipopolysaccharide binding protein in hepatocellular carcinoma. Oncol Lett 2020;19:159-66. [PMID: 31897126 DOI: 10.3892/ol.2019.11119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
140 Li Y, Ding X, Xiu S, Du G, Liu Y. LncRNA NEAT1 Promotes Proliferation, Migration And Invasion Via Regulating miR-296-5p/CNN2 Axis In Hepatocellular Carcinoma Cells. Onco Targets Ther 2019;12:9887-97. [PMID: 31819486 DOI: 10.2147/OTT.S228917] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
141 Sun J, Liu L, Zou H, Yu W. The Long Non-Coding RNA CASC2 Suppresses Cell Viability, Migration, and Invasion in Hepatocellular Carcinoma Cells by Directly Downregulating miR-183. Yonsei Med J 2019;60:905-13. [PMID: 31538425 DOI: 10.3349/ymj.2019.60.10.905] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
142 Zhao Z, Dai J, Yu Y, Zhang Q, Liu S, Huang G, Zhang Z, Chen T, Pan R, Lu L, Zhang W, Liao W, Lu X. Non-invasive Bioluminescence Monitoring of Hepatocellular Carcinoma Therapy in an HCR Mouse Model. Front Oncol 2019;9:864. [PMID: 31572672 DOI: 10.3389/fonc.2019.00864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Chen C, Wang Y, Li G, Xu L, Wang Y, Huang H, Wang B, Li W, He X. Feasibility of CT-CT fusion imaging for evaluation of the cryoablation margins in visible hepatocellular carcinoma on unenhanced CT images: Initial experience. J Interv Med 2019;2:60-4. [PMID: 34805874 DOI: 10.1016/j.jimed.2019.09.003] [Reference Citation Analysis]
144 Zhang Z, Wen H, Weng J, Feng L, Liu H, Hu X, Zeng F. Silencing of EPCAM suppresses hepatic fibrosis and hepatic stellate cell proliferation in mice with alcoholic hepatitis via the PI3K/Akt/mTOR signaling pathway. Cell Cycle 2019;18:2239-54. [PMID: 31378124 DOI: 10.1080/15384101.2019.1642067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
145 Zhao L, Wang Y, Liu Q. Catalpol inhibits cell proliferation, invasion and migration through regulating miR-22-3p/MTA3 signalling in hepatocellular carcinoma. Experimental and Molecular Pathology 2019;109:51-60. [DOI: 10.1016/j.yexmp.2019.104265] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
146 Xie S, Jiang X, Zhang J, Xie S, Hua Y, Wang R, Yang Y. Identification of significant gene and pathways involved in HBV-related hepatocellular carcinoma by bioinformatics analysis. PeerJ 2019;7:e7408. [PMID: 31392101 DOI: 10.7717/peerj.7408] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
147 Neureiter D, Stintzing S, Kiesslich T, Ocker M. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol 2019; 25(25): 3136-3150 [PMID: 31333307 DOI: 10.3748/wjg.v25.i25.3136] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 39] [Article Influence: 11.7] [Reference Citation Analysis]
148 He L, Fan X, Li Y, Chen M, Cui B, Chen G, Dai Y, Zhou D, Hu X, Lin H. Overexpression of zinc finger protein 384 (ZNF 384), a poor prognostic predictor, promotes cell growth by upregulating the expression of Cyclin D1 in Hepatocellular carcinoma. Cell Death Dis 2019;10:444. [PMID: 31168049 DOI: 10.1038/s41419-019-1681-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
149 Tang W, Yang L, Yang T, Liu M, Zhou Y, Lin J, Wang K, Ding C. INPP4B inhibits cell proliferation, invasion and chemoresistance in human hepatocellular carcinoma. Onco Targets Ther 2019;12:3491-507. [PMID: 31123408 DOI: 10.2147/OTT.S196832] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
150 Yu B, Ding Y, Liao X, Wang C, Wang B, Chen X. Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma. Dig Dis Sci 2019;64:2878-92. [DOI: 10.1007/s10620-019-05608-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
151 Chen J, Wu Y, Li S, Wu H, Li L. [10-gingerol inhibits proliferation of hepatocellular carcinoma HepG2 cells via Src/STAT3 signaling pathway]. Nan Fang Yi Ke Da Xue Xue Bao 2018;38:1002-7. [PMID: 30187878 DOI: 10.3969/j.issn.1673-4254.2018.08.17] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
152 Wu DD, Wang DY, Li HM, Guo JC, Duan SF, Ji XY. Hydrogen Sulfide as a Novel Regulatory Factor in Liver Health and Disease. Oxid Med Cell Longev 2019;2019:3831713. [PMID: 30805080 DOI: 10.1155/2019/3831713] [Cited by in Crossref: 11] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
153 George J, Tsuchishima M, Tsutsumi M. Molecular mechanisms in the pathogenesis of N-nitrosodimethylamine induced hepatic fibrosis. Cell Death Dis 2019;10:18. [PMID: 30622238 DOI: 10.1038/s41419-018-1272-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]
154 Li S, Gu H, Huang Y, Peng Q, Zhou R, Yi P, Chen R, Huang Z, Hu X, Huang Y, Tang D. Circular RNA 101368/miR-200a axis modulates the migration of hepatocellular carcinoma through HMGB1/RAGE signaling. Cell Cycle. 2018;17:2349-2359. [PMID: 30265210 DOI: 10.1080/15384101.2018.1526599] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
155 Li Q, Wang W, Hu YC, Yin TT, He J. Knockdown of Ubiquitin Associated Protein 2-Like (UBAP2L) Inhibits Growth and Metastasis of Hepatocellular Carcinoma. Med Sci Monit. 2018;24:7109-7118. [PMID: 30291221 DOI: 10.12659/msm.912861] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
156 Ocker M. Biomarkers for hepatocellular carcinoma: What’s new on the horizon? World J Gastroenterol 2018; 24(35): 3974-3979 [PMID: 30254402 DOI: 10.3748/wjg.v24.i35.3974] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
157 Zhang YQ, Shen Y, Liao MM, Mao X, Mi GJ, You C, Guo QY, Li WJ, Wang XY, Lin N, Webster TJ. Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms. Nanomedicine 2019;15:86-97. [PMID: 30244085 DOI: 10.1016/j.nano.2018.09.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
158 Garden OA, Volk SW, Mason NJ, Perry JA. Companion animals in comparative oncology: One Medicine in action. Vet J 2018;240:6-13. [PMID: 30268334 DOI: 10.1016/j.tvjl.2018.08.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
159 Zhang Z, Xie Q, He D, Ling Y, Li Y, Li J, Zhang H. Circular RNA: New star, new hope in cancer. BMC Cancer. 2018;18:834. [PMID: 30126353 DOI: 10.1186/s12885-018-4689-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 54] [Article Influence: 10.5] [Reference Citation Analysis]
160 Yoo GS, Yu JI, Park HC. Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives. World J Gastroenterol 2018; 24(28): 3090-3100 [PMID: 30065555 DOI: 10.3748/wjg.v24.i28.3090] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
161 Zheng J, Sadot E, Vigidal JA, Klimstra DS, Balachandran VP, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Jarnagin WR, Ventura A. Characterization of hepatocellular adenoma and carcinoma using microRNA profiling and targeted gene sequencing. PLoS One 2018;13:e0200776. [PMID: 30052636 DOI: 10.1371/journal.pone.0200776] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
162 Umeh-Garcia M, Sweeney C. Cancer prevention through miRNAs: miR-206 prevents the initiation and progression of hepatocellular carcinoma by attenuating c-MET signaling and cell-cycle progression via cyclin D1 and CDK6. Noncoding RNA Investig 2018;2:37. [PMID: 31930188 DOI: 10.21037/ncri.2018.06.05] [Reference Citation Analysis]
163 Zhu Q, Yu X, Zhou ZW, Luo M, Zhou C, He ZX, Chen Y, Zhou SF. A quantitative proteomic response of hepatocellular carcinoma Hep3B cells to danusertib, a pan-Aurora kinase inhibitor. J Cancer 2018;9:2061-71. [PMID: 29937924 DOI: 10.7150/jca.20822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
164 Caja L, Dituri F, Mancarella S, Caballero-Diaz D, Moustakas A, Giannelli G, Fabregat I. TGF-β and the Tissue Microenvironment: Relevance in Fibrosis and Cancer. Int J Mol Sci 2018;19:E1294. [PMID: 29701666 DOI: 10.3390/ijms19051294] [Cited by in Crossref: 100] [Cited by in F6Publishing: 132] [Article Influence: 25.0] [Reference Citation Analysis]
165 Nakagawa H, Fujita M, Fujimoto A. Genome sequencing analysis of liver cancer for precision medicine. Semin Cancer Biol 2019;55:120-7. [PMID: 29605648 DOI: 10.1016/j.semcancer.2018.03.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
166 Ikeda S, Lim JS, Kurzrock R. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. Mol Cancer Ther 2018;17:1114-22. [PMID: 29483209 DOI: 10.1158/1535-7163.MCT-17-0604] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
167 Sukocheva OA. Estrogen, estrogen receptors, and hepatocellular carcinoma: Are we there yet? World J Gastroenterol 2018;24:1-4. [PMID: 29358876 DOI: 10.3748/wjg.v24.i1.1] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
168 Monzavi N, Zargar SJ, Gheibi N, Azad M, Rahmani B. Angiopoietin-like protein 8 (betatrophin) may inhibit hepatocellular carcinoma through suppressing of the Wnt signaling pathway. Iran J Basic Med Sci 2019;22:1166-71. [PMID: 31998458 DOI: 10.22038/ijbms.2019.36612.8764] [Cited by in F6Publishing: 4] [Reference Citation Analysis]